Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

PURPOSE: To explore whether patients with BRCA1/2-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial. PATIENTS AND METHODS: Patients with newly diagnosed ovarian cancer were randomized to either atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Landen, Charles N., Molinero, Luciana, Hamidi, Habib, Sehouli, Jalid, Miller, Austin, Moore, Kathleen N., Taskiran, Cagatay, Bookman, Michael, Lindemann, Kristina, Anderson, Charles, Berger, Regina, Myers, Tashanna, Beiner, Mario, Reid, Thomas, Van Nieuwenhuysen, Els, Green, Andrew, Okamoto, Aikou, Aghajanian, Carol, Thaker, Premal H., Blank, Stephanie V., Khor, Victor K., Chang, Ching-Wei, Lin, Yvonne G., Pignata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150250/
https://www.ncbi.nlm.nih.gov/pubmed/36595569
http://dx.doi.org/10.1158/1078-0432.CCR-22-2032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150250/
https://www.ncbi.nlm.nih.gov/pubmed/36595569
http://dx.doi.org/10.1158/1078-0432.CCR-22-2032

Ejemplares similares